@article{70418feb469d4fbeae682197cf8cd3db,
title = "Sarcopenia Definition & Outcomes Consortium Defined Low Grip Strength in Two Cross-Sectional, Population-Based Cohorts",
abstract = "BACKGROUND/OBJECTIVES: The extent to which the prevalence of muscle weakness in the US population varies by different putative grip strength constructs developed by the Sarcopenia Definitions and Outcomes Consortium (SDOC) has not been described. DESIGN: Cross-sectional analysis. SETTING: Two nationally representative cohorts—2010 and 2012 waves of the Health and Retirement Survey and round 1 (2011) of the National Health and Aging Trends Survey. PARTICIPANTS: Adults aged 65 years and older (n = 12,984) were included in these analyses. MEASUREMENTS: We analyzed three constructs of muscle weakness developed by the SDOC, and found to be associated with mobility disability for men and women, respectively: absolute grip strength (<35.5 kg and 20 kg); grip strength standardized to body mass index (<1.05 kg/kg/m² and 0.79 kg/kg/m²); and grip strength standardized to weight (<0.45 kg/kg and 0.337 kg/kg). We estimated the prevalence of muscle weakness defined by each of these constructs in the overall older US population, and by age, sex, race, and ethnicity. We also estimated the sensitivity and specificity of each of the grip strength constructs to discriminate slowness (gait speed <0.8 m/s) in these samples. RESULTS: The prevalence of muscle weakness ranged from 23% to 61% for men and from 30% to 66% for women, depending on the construct used. There was substantial variation in the prevalence of muscle weakness by race and ethnicity. The sensitivity and specificity of these measures for discriminating slowness varied widely, ranging from 0.30 to 0.92 (sensitivity) and from 0.17 to 0.88 (specificity). CONCLUSIONS: The prevalence of muscle weakness, defined by the putative SDOC grip strength constructs, depends on the construct of weakness used. J Am Geriatr Soc 68:1438-1444, 2020.",
keywords = "gait, muscle, physical performance, sarcopenia",
author = "Patel, {Sheena M.} and Duchowny, {Kate A.} and Kiel, {Douglas P.} and Rosaly Correa-de-Araujo and Fielding, {Roger A.} and Thomas Travison and Jay Magaziner and Todd Manini and Xue, {Qian Li} and Newman, {Anne B.} and Pencina, {Karol M.} and Santanasto, {Adam J.} and Shalender Bhasin and Cawthon, {Peggy M.}",
note = "Funding Information: The Sarcopenia Definitions and Outcomes Consortium is supported by the National Institute on Aging (grant AG51421), the Foundation for the National of Institutes of Health (grants CAWT16SARC2 and BHAS16SARC2), and the California Pacific Medical Center Foundation. Funding Information: R.A.F. reports grants from National Institutes of Health (National Institute on Aging) and the US Department of Agriculture, during the conduct of the study; grants, personal fees, and other from Axcella Health, other from Inside Tracker, grants and personal fees from Biophytis, grants and personal fees from Astellas, personal fees from Cytokinetics, personal fees from Amazentis, grants and personal fees from Nestle', and personal fees from Glaxo Smith Kline, outside the submitted work. Funding Information: A.J.S. was supported by a career development award from the National Institutes of Health/National Institute on Aging (K01 AG057726). Funding Information: The Sarcopenia Definitions and Outcomes Consortium is supported by the National Institute on Aging (grant AG51421), the Foundation for the National of Institutes of Health (grants CAWT16SARC2 and BHAS16SARC2), and the California Pacific Medical Center Foundation. P.M.C. serves as a consultant for Bioage, and had grants to her institution from Abbott and Nestle. K.M.E. has served as a consultant for Gilead and ViiV Pharmaceuticals, and is supported by the National Institutes of Health, National Institute on Aging K23 AG050260 and R01 AG054366. S.B. has received grant support for investigator-initiated research from the National Institute on Aging, National Institute of Nursing Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Foundation for the National Institutes of Health, Patient-Centered Outcomes Research Institute, Abbvie, Transition Therapeutics, Abbott, Metro International Biotechnology, LLC, and Alivegen. These grants and contracts are managed by the Brigham and Women's Hospital. He reports receiving consulting fees from AbbVie and OPKO and holding equity interest in FPT, LLC. R.A.F. reports grants from National Institutes of Health (National Institute on Aging) and the US Department of Agriculture, during the conduct of the study; grants, personal fees, and other from Axcella Health, other from Inside Tracker, grants and personal fees from Biophytis, grants and personal fees from Astellas, personal fees from Cytokinetics, personal fees from Amazentis, grants and personal fees from Nestle', and personal fees from Glaxo Smith Kline, outside the submitted work. D.P.K. reports royalty payments from Wolters Kluwer for contributions to UpToDate chapter on Falls. He has received a stipend from Springer for editor roles on the book, Osteoporosis in Older Persons. He has received consultant payments for serving on a scientific advisory board for Solarea Bio. He has received grant support to his institution from the Dairy Council, Policy Analysis, Inc, and Radius Health. J.S.M. consulted or served on advisory boards for: American Orthopedic Association; Novartis; Pluristem; and Viking. None of these entities provided funding for the current project. All other authors report no conflicts. A.J.S. was supported by a career development award from the National Institutes of Health/National Institute on Aging (K01 AG057726). S.M.P., S.B., P.M.C., and K.D.: study conception and design and drafting and critical review of manuscript; S.M.P.: statistical analysis; all other authors: critical review of manuscript; S.B. and P.M.C.: project funding. The sponsors of this work had no role in the analysis or interpretation of results and no role in the decision to publish these data. Funding Information: S.B. has received grant support for investigator‐initiated research from the National Institute on Aging, National Institute of Nursing Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Foundation for the National Institutes of Health, Patient‐Centered Outcomes Research Institute, Abbvie, Transition Therapeutics, Abbott, Metro International Biotechnology, LLC, and Alivegen. These grants and contracts are managed by the Brigham and Women's Hospital. He reports receiving consulting fees from AbbVie and OPKO and holding equity interest in FPT, LLC. Funding Information: K.M.E. has served as a consultant for Gilead and ViiV Pharmaceuticals, and is supported by the National Institutes of Health, National Institute on Aging K23 AG050260 and R01 AG054366. Publisher Copyright: {\textcopyright} 2020 The American Geriatrics Society",
year = "2020",
month = jul,
day = "1",
doi = "10.1111/jgs.16419",
language = "English (US)",
volume = "68",
pages = "1438--1444",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "7",
}